Product
Regadenoson
Name
Regadenoson
INN Name
Regadenoson
FDA Approved
Yes
6 clinical trials
11 organizations
11 indications
2 documents
Indication
Myocardial InfarctionIndication
Coronary Artery DiseaseIndication
High-Grade GliomaIndication
Anaplastic AstrocytomaIndication
OligodendrogliomaIndication
GlioblastomaIndication
Myocardial Perfusion AbnormalitiesIndication
IschemiaIndication
COVID-19Indication
Lung InflammationIndication
Heart Transplant RejectionClinical trial
An Open-label, Single-dose, Safety and Pharmacokinetic Study of Regadenoson in Pediatric PatientsStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade GliomasStatus: Terminated, Estimated PCD: 2022-04-30
Clinical trial
Regadenoson Stress Real-Time Myocardial Perfusion Echocardiography for Detection of Coronary Artery Disease Feasibility and Accuracy of Two Different Ultrasound Contrast AgentsStatus: Completed, Estimated PCD: 2014-04-01
Clinical trial
Use of Regadenoson for a Stress Echocardiogram Protocol Using Speckle Tracking ImagingStatus: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
Clinical Trial on the Safety and Efficacy of Regadenoson for Moderate to Severe COVID-19 Adult PatientsStatus: Completed, Estimated PCD: 2023-04-24
Clinical trial
Defining Mechanisms for Cardiac Allograft Dysfunction to Improve Allograft Longevity and Survival in Heart-Transplant PatientsStatus: Recruiting, Estimated PCD: 2024-12-01
Organization
Dr. Reddy's Laboratories Inc.Document
DailyMed Label: RegadenosonOrganization
Meitheal Pharmaceuticals Inc.Document
DailyMed Label: RegadenosonOrganization
Gland Pharma LimitedOrganization
International Medication Systems, LimitedOrganization
Eugia US LLCOrganization
Apotex Corp.Organization
ALMAJECT, INC.Organization
Baxter Healthcare Corporation
Organization
Mylan Institutional LLCOrganization
Hikma Pharmaceuticals USA Inc.Organization
Hospira, Inc.